|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H, Zou X, Zhang S
and He J: Report of Cancer Incidence and Mortality in China, 2011.
China Cancer. 24:1–10. 2012. View Article : Google Scholar
|
|
3
|
Larsson R, Mongan NP, Johansson M,
Shcherbina L, Abrahamsson PA, Gudas LJ, Sterner O and Persson JL:
Clinical trial update and novel therapeutic approaches for
metastatic prostate cancer. Curr Med Chem. 18:4440–4453. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rice MA, Malhotra SV and Stoyanova T:
Second-Generation Antiandrogens: From Discovery to Standard of Care
in Castration Resistant Prostate Cancer. Front Oncol. 9:8012019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al TAX 327 Investigators, : Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scher HI, Morris MJ, Stadler WM, Higano C,
Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, et
al: Trial design and objectives for castration-resistant prostate
cancer: updated recommendations from the prostate cancer clinical
trials working group 3. J Clin Oncol. 34:1402–1418. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higano CS, Beer TM, Taplin ME, Efstathiou
E, Hirmand M, Forer D and Scher HI: Long-term safety and antitumor
activity in the Phase1-2 study of enzalutamide in pre- and
post-docetaxel castration-resistant prostate cancer. Eur Urol.
68:795–801. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ryan CJ, Smith MR, de Bono JS, Molina A,
Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng
S, et al COU-AA-302 Investigators, : Abiraterone in metastatic
prostate cancer without previous chemotherapy. N Engl J Med.
368:138–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ryan CJ, Smith MR, Fizazi K, Saad F,
Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small
EJ, et al COU-AA-302 Investigators, : Abiraterone acetate plus
prednisone versus placebo plus prednisone in chemotherapy-naive men
with metastatic castration-resistant prostate cancer (COU-AA-302):
Final overall survival analysis of a randomised, double-blind,
placebo-controlled phase 3 study. Lancet Oncol. 16:152–160. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hussain M, Tangen CM, Higano C,
Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small
EJ, Donnelly B, et al Southwest Oncology Group Trial 9346
(INT-0162), : Absolute prostate-specific antigen value after
androgen deprivation is a strong independent predictor of survival
in new metastatic prostate cancer: Data from Southwest Oncology
Group Trial 9346 (INT-0162). J Clin Oncol. 24:3984–3990. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Y, Lan F, Matson C, Mulligan P,
Whetstine JR, Cole PA, Casero RA and Shi Y: Histone demethylation
mediated by the nuclear amine oxidase homolog LSD1. Cell.
119:941–953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang M, Liu X, Jiang G, Chen H, Guo J and
Weng X: Relationship between LSD1 expression and E-cadherin
expression in prostate cancer. Int Urol Nephrol. 47:485–490. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang M, Liu X, Guo J, Weng X, Jiang G,
Wang Z and He L: Inhibition of LSD1 by Pargyline inhibited process
of EMT and delayed progression of prostate cancer in vivo. Biochem
Biophys Res Commun. 467:310–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Metzger E, Wissmann M, Yin N, Müller JM,
Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1
demethylates repressive histone marks to promote
androgen-receptor-dependent transcription. Nature. 437:436–439.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Metzger E, Imhof A, Patel D, Kahl P,
Hoffmeyer K, Friedrichs N, Müller JM, Greschik H, Kirfel J, Ji S,
et al: Phosphorylation of histone H3T6 by PKCbeta(I) controls
demethylation at histone H3K4. Nature. 464:792–796. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kahl P, Gullotti L, Heukamp LC, Wolf S,
Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J,
Metzger E, et al: Androgen receptor coactivators lysine-specific
histone demethylase 1 and four and a half LIM domain protein 2
predict risk of prostate cancer recurrence. Cancer Res.
66:11341–11347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schaeffer EM, Marchionni L, Huang Z,
Simons B, Blackman A, Yu W, Parmigiani G and Berman DM:
Androgen-induced programs for prostate epithelial growth and
invasion arise in embryogenesis and are reactivated in cancer.
Oncogene. 27:7180–7191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Green SM, Mostaghel EA and Nelson PS:
Androgen action and metabolism in prostate cancer. Mol Cell
Endocrinol. 360:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knudsen KE, Arden KC and Cavenee WK:
Multiple G1 regulatory elements control the androgen-dependent
proliferation of prostatic carcinoma cells. J Biol Chem.
273:20213–20222. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Y, Chen SY, Ross KN and Balk SP:
Androgens induce prostate cancer cell proliferation through
mammalian target of rapamycin activation and post-transcriptional
increases in cyclin D proteins. Cancer Res. 66:7783–7792. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang J, Sengupta R, Espejo AB, Lee MG,
Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT,
Jenuwein T, et al: p53 is regulated by the lysine demethylase LSD1.
Nature. 449:105–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scoumanne A and Chen X: The
lysine-specific demethylase 1 is required for cell proliferation in
both p53-dependent and -independent manners. J Biol Chem.
282:15471–15475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schulte JH, Lim S, Schramm A, Friedrichs
N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L,
Kuhfittig-Kulle S, et al: Lysine-specific demethylase 1 is strongly
expressed in poorly differentiated neuroblastoma: Implications for
therapy. Cancer Res. 69:2065–2071. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayami S, Kelly JD, Cho HS, Yoshimatsu M,
Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al:
Overexpression of LSD1 contributes to human carcinogenesis through
chromatin regulation in various cancers. Int J Cancer. 128:574–586.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bennani-Baiti IM, Machado I,
Llombart-Bosch A and Kovar H: Lysine-specific demethylase 1
(LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug
target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and
rhabdomyosarcoma. Hum Pathol. 43:1300–1307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y,
Chen S, Chen MW, Zhang J, Ahmed M, et al: Lysine-specific
demethylase 1 has dual functions as a major regulator of androgen
receptor transcriptional activity. Cell Rep. 9:1618–1627. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McConkey DJ, Orrenius S and Jondal M:
Cellular signalling in programmed cell death (apoptosis). Immunol
Today. 11:120–121. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Strobel T, Swanson L, Korsmeyer S and
Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a
p53-independent pathway. Proc Natl Acad Sci USA. 93:14094–14099.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Antonsson B and Martinou JC: The Bcl-2
protein family. Exp Cell Res. 256:50–57. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin T, Ponn A, Hu X, Law BK and Lu J:
Requirement of the histone demethylase LSD1 in Snai1-mediated
transcriptional repression during epithelial-mesenchymal
transition. Oncogene. 29:4896–4904. 2010. View Article : Google Scholar : PubMed/NCBI
|
